AstraZeneca Signs US$1.77 B Renal Disease Licensing Pact with CSPC Pharmaceutical Group

By Nikita Negi

Pharma Deals Review: Vol 2026 Issue 7 (Table of Contents)

Published: 20 Jul-2026

DOI: 10.3833/pdr.v2026.i7.3024     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

In an effort to expand its presence in renal diseases and strengthen its nucleic acid therapeutics pipeline, AstraZeneca has signed a collaboration, option and license agreement with CSPC Pharmaceutical Group to develop a novel small nucleic acid drug candidate for kidney disorders...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details